Moderna
MRNA
#1769
Rank
NZ$19.50 B
Marketcap
NZ$49.92
Share price
2.80%
Change (1 day)
-30.23%
Change (1 year)
Moderna, Inc. is an American biotechnology company focused on the discovery and development of messenger RNA-based drugs.

Revenue for Moderna (MRNA)

Revenue in 2025 (TTM): NZ$3.83 Billion

According to Moderna 's latest financial reports the company's current revenue (TTM ) is NZ$3.78 Billion. In 2024 the company made a revenue of NZ$5.67 Billion a decrease over the revenue in the year 2023 that were of NZ$10.67 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Moderna from 2018 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) NZ$3.83 B-32.35%
2024 NZ$5.67 B-46.89%
2023 NZ$10.67 B-64.08%
2022 NZ$29.72 B14.49%
2021 NZ$25.96 B6728.48%
2020 NZ$0.38 B433.14%
2019 NZ$71.32 M-61.03%
2018 NZ$0.18 B

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Regulus Therapeutics
RGLS
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Merck
MRK
NZ$110.45 B 2,817.12%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
NZ$0.13 M-100.00%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
NZ$5.51 B 45.78%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
NZ$96.93 B 2,460.04%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Arrowhead Pharmaceuticals
ARWR
NZ$0.98 B-73.98%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
NZ$158.45 B 4,084.79%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
NZ$0.33 B-91.24%๐Ÿ‡บ๐Ÿ‡ธ USA